Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
at aura biosciences, we are developing a new class of therapies to target and destroy cancer cells selectively, while leaving surrounding tissue unharmed – an approach we call molecular surgery. by safely eliminating cancer locally, we can treat early and transform the lives of people with a wide range of cancers that are poorly managed today. our lead program in ocular melanoma (om), also known as choroidal or uveal melanoma, is designed to remove cancer cells in the back of the eye as a first-line therapy, while allowing for the potential of preserving patients’ vision. the goal is to treat small ocular melanomas potentially long before the disease progresses and metastasizes to the liver, where it almost always is fatal. development of a first-in-class, non-radioactive treatment option to selectively destroy cancer cells would create the possibility to transform the treatment of this and other cancers where the disease can be detected early. by enabling physicians to treat cancer mo